Similarly, olaparib, a PARP inhibitor, was not approved as a monotherapy for mCRPC following a positive Breast Cancer Gene 1 and Breast Cancer Gene 2 (BRCA1/2) mutation analysis, necessitating tumor board recommendations to facilitate cost coverage. The gene discussed is BRCA1; the disease is breast cancer.